帕金森病(PD)和路易体痴呆(DLB)具有潜在的神经病理学特征。尽管生物学重叠,对于这些临床综合征,已经分别进行了治疗开发,并且仍然没有治疗方法来减缓,阻止或预防PD或DLB患者的临床症状进展和发育障碍。生物标志物工具的最新进展,然而,在共同的研究框架下,为PD和DLB的生物学定义和分期铺平了新的道路。以患者为中心的研究资助组织看到了用于PD和DLB的新型生物分期系统的机会,以加速并增加他们所服务的患者社区的治疗开发的成功。在为这些神经退行性疾病制定生物学定义的领域中,7个专注于PD和DLB的国际非营利组织聚集在一起,推动多方利益相关者讨论和输入关于生物分期系统的研究。迄今为止,这些会议的影响可以在纳入拟议的生物分期系统的变化中看到,并在该领域内迅速应用新的科学知识和生物标志物工具来为临床试验设计提供信息。在一起工作,最初被生物分期系统的巨大潜力所催化的志同道合的非营利合作伙伴也意识到了共同的声音在呼吁该领域采取行动方面的力量,并此后共同努力建立了一个联盟,以推进竞争前的进展并减少开发更好的障碍PD治疗,DLB和生物学相关疾病。简单的语言摘要。以疾病为中心的非营利组织通过研究资金和倡导来加快患者的新疗法。在帕金森病(PD)和路易体痴呆(DLB)领域,几个国际非营利组织聚集在一起,以促进多方利益相关者对新的生物分期系统进行研究的投入。收集的利益相关者包括研究人员,临床医生,药物开发商,监管机构,额外的非营利组织,以及受PD和DLB影响的人。这个例子,在一个共同的观点的推动下,新药开发工具将改善临床试验,并更快地为患者提供更好的治疗,作为跨PD和DLB领域持续合作的模型。一个新的,非营利组织的国际联盟已经出现,以支持减缓治疗的进展,停止,有一天预防PD,DLB和相关疾病,在某种程度上,通过促进未来的多利益相关方合作。
Parkinson\'s disease (PD) and dementia with Lewy bodies (DLB) share underlying neuropathology. Despite overlapping biology, therapeutic development has been approached separately for these clinical syndromes and there remains no treatment to slow, stop or prevent progression of clinical symptoms and development disability for people living with PD or DLB. Recent advances in biomarker tools, however, have paved new paths for biologic definition and staging of PD and DLB under a shared research framework. Patient-centered research funding organizations see the opportunity for a novel biological staging system for PD and DLB to accelerate and increase success of therapeutic development for the patient communities they serve. Amid growing momentum in the field to develop biological definitions for these neurodegenerative diseases, 7 international nonprofit organizations focused on PD and DLB came together to drive multistakeholder discussion and input on a biological staging system for research. The impact of these convenings to date can be seen in changes incorporated into a proposed biological staging system and growing alignment within the field to rapidly apply new scientific knowledge and biomarker tools to inform clinical trial design. In working together, likeminded nonprofit partners who were initially catalyzed by the significant potential for a biological staging system also realized the power of a shared voice in calling the field to action and have since worked together to establish a coalition to advance precompetitive progress and reduce hurdles to developing better treatments for PD, DLB and biologically related disorders. Plain Language Summary. Disease-focused nonprofit organizations serve to speed new treatments for patients through research funding and advocacy. In the Parkinson\'s disease (PD) and dementia with Lewy bodies (DLB) fields, several international nonprofit organizations came together to facilitate multistakeholder input on a new biological staging system for research. Stakeholders gathered included researchers, clinicians, drug developers, regulatory agencies, additional nonprofits, and people affected by PD and DLB. This example, fueled by a shared perspective that new drug development tools will improve clinical trials and get better treatments to patients sooner, serves as a model for continued collaborations across the PD and DLB fields. A new, international coalition of nonprofit organizations has emerged to support advancement of treatments to slow, stop, and one day prevent PD, DLB and related disorders, in part, by facilitating future multistakeholder collaborations.